AMPH Amphastar Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AMPH

Price (delayed)

$40.05

Market cap

$1.93B

P/E Ratio

14.05

Dividend/share

N/A

EPS

$2.85

Enterprise value

$2.41B

Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active ...

Highlights
The stock's P/E is 84% less than its 5-year quarterly average of 88.7 and 34% less than its last 4 quarters average of 21.3
The EPS has soared by 52% YoY and by 2.2% from the previous quarter
Amphastar Pharmaceuticals's quick ratio has decreased by 41% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.amphastar.com
Peers: SCYX RGLS MRNS

Key stats

What are the main financial stats of AMPH
Market
Shares outstanding
48.1M
Market cap
$1.93B
Enterprise value
$2.41B
Valuations
Price to earnings (P/E)
14.05
Price to book (P/B)
3
Price to sales (P/S)
3
EV/EBIT
12.24
EV/EBITDA
10.67
EV/Sales
3.73
Earnings
Revenue
$644.4M
EBIT
$196.54M
EBITDA
$225.48M
Free cash flow
$145.34M
Per share
EPS
$2.85
Free cash flow per share
$3.01
Book value per share
$13.35
Revenue per share
$13.35
TBVPS
$18.64
Balance sheet
Total assets
$1.51B
Total liabilities
$873.49M
Debt
$623.64M
Equity
$639.42M
Working capital
$264.19M
Liquidity
Debt to equity
0.98
Current ratio
2.17
Quick ratio
1.66
Net debt/EBITDA
2.12
Margins
EBITDA margin
35%
Gross margin
54.5%
Net margin
21.3%
Operating margin
30.6%
Efficiency
Return on assets
10.6%
Return on equity
23.2%
Return on invested capital
21.5%
Return on capital employed
15.3%
Return on sales
30.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AMPH stock price

How has the Amphastar Pharmaceuticals stock price performed over time
Intraday
-2.08%
1 week
0%
1 month
-6.97%
1 year
-4.55%
YTD
-35.25%
QTD
-8.79%

Financial performance

How have Amphastar Pharmaceuticals's revenue and profit performed over time
Revenue
$644.4M
Gross profit
$351.12M
Operating income
$196.99M
Net income
$137.55M
Gross margin
54.5%
Net margin
21.3%
The operating income has surged by 83% year-on-year and by 9% since the previous quarter
The net income has soared by 51% YoY
AMPH's operating margin is up by 42% year-on-year
The company's gross profit rose by 41% YoY and by 8% QoQ

Growth

What is Amphastar Pharmaceuticals's growth rate over time

Valuation

What is Amphastar Pharmaceuticals stock price valuation
AMPH P/E details
P/E
14.05
P/B
3
P/S
3
EV/EBIT
12.24
EV/EBITDA
10.67
EV/Sales
3.73
The stock's P/E is 84% less than its 5-year quarterly average of 88.7 and 34% less than its last 4 quarters average of 21.3
The EPS has soared by 52% YoY and by 2.2% from the previous quarter
The price to book (P/B) is 27% lower than the last 4 quarters average of 4.1 but 7% higher than the 5-year quarterly average of 2.8
Amphastar Pharmaceuticals's equity has increased by 21% YoY and by 7% from the previous quarter
Amphastar Pharmaceuticals's revenue has increased by 29% YoY and by 7% QoQ
AMPH's price to sales (P/S) is 29% less than its last 4 quarters average of 4.2 and 3.2% less than its 5-year quarterly average of 3.1

Efficiency

How efficient is Amphastar Pharmaceuticals business performance
The ROS has grown by 30% YoY but it has contracted by 2.6% from the previous quarter
The ROE has grown by 27% YoY but it has contracted by 2.9% from the previous quarter
The company's return on assets fell by 16% YoY and by 13% QoQ
The ROIC is down by 13% since the previous quarter and by 3.2% year-on-year

Dividends

What is AMPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AMPH.

Financial health

How did Amphastar Pharmaceuticals financials performed over time
The total assets is 73% greater than the total liabilities
The total assets has surged by 104% year-on-year but it has declined by 2.1% since the previous quarter
Amphastar Pharmaceuticals's current ratio has decreased by 46% YoY but it has increased by 3.3% from the previous quarter
AMPH's debt is 2.5% smaller than its equity
Amphastar Pharmaceuticals's equity has increased by 21% YoY and by 7% from the previous quarter
Amphastar Pharmaceuticals's debt to equity has decreased by 13% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.